Avience Biomedicals Limited (NSE:AVIENCE)

Avience Biomedicals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	29.34	49.37	3.57	2.45	0.25
Cash & Short-Term Investments	29.34	49.37	3.57	2.45	0.25
Cash Growth	-40.56%	1283.55%	45.77%	883.44%	-64.55%
Accounts Receivable	210.17	172.11	80.91	18.07	25.3
Other Receivables	1.51	0.9	0.6	0.07	-
Receivables	214.04	176.11	84.1	20.21	25.3
Inventory	171.75	130.71	123.95	35.44	14.69
Prepaid Expenses	3.82	1.66	0.06	0.04	-
Other Current Assets	12.69	13.89	18.73	10.68	5.38
Total Current Assets	431.64	371.72	230.4	68.81	45.61
Property, Plant & Equipment	287.69	175.78	101.46	25.18	11.63
Long-Term Investments	0.28	0.28	2.88	1.12	-
Goodwill	1.45	1.45	1.45	-	-
Long-Term Deferred Tax Assets	0.35	0.74	1.08	-	-
Other Long-Term Assets	24.29	14.92	9.24	5.03	3.68
Total Assets	745.68	564.88	346.51	100.15	60.93

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	94.75	72.68	55.49	12.72	2.29
Accrued Expenses	9.29	10.1	5.21	1.19	0.86
Short-Term Debt	140.81	114.99	69.75	24.87	23.18
Current Portion of Long-Term Debt	16.25	8.1	8.71	0.21	-
Current Income Taxes Payable	33.09	25.47	6.63	0.59	0.81
Current Unearned Revenue	-	1.5	1.5	-	-
Other Current Liabilities	1.63	3.08	60.72	17.76	3.8
Total Current Liabilities	295.81	235.92	208.02	57.34	30.94
Long-Term Debt	132.29	98.5	72.84	1.49	1.7
Pension & Post-Retirement Benefits	1.42	2.25	2.18	-	0.02
Long-Term Deferred Tax Liabilities	1.86	1.47	1.19	0.54	0.21
Other Long-Term Liabilities	0.18	0.16	0	0.1	0.14
Total Liabilities	431.56	338.29	284.23	59.47	33.01

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	40.31	40.31	32.85	32.85	20.35
Additional Paid-In Capital	85.88	85.88	-	-	-
Retained Earnings	187.94	100.41	29.43	7.83	7.58
Shareholders' Equity	314.13	226.6	62.28	40.68	27.92
Total Liabilities & Equity	745.68	564.88	346.51	100.15	60.93

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	289.35	221.58	151.31	26.57	24.88
Net Cash (Debt)	-260	-172.22	-147.74	-24.12	-24.64
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-64.50	-45.39	-44.98	-9.04	-18.31
Filing Date Shares Outstanding	5.49	4.03	3.28	3.28	2.64
Total Common Shares Outstanding	4.03	4.03	3.28	3.28	2.64
Working Capital	135.82	135.81	22.38	11.47	14.67
Book Value Per Share	77.92	56.21	18.96	12.38	10.59
Tangible Book Value	312.68	225.15	60.83	40.68	27.92
Tangible Book Value Per Share	77.56	55.85	18.52	12.38	10.59
Land	29.29	28.69	40.99	-	-
Machinery	153.43	112.31	84.18	28.32	12.68
Construction In Progress	128.53	46.19	0.28	-	-

Data Source: S&P Global Market Intelligence Last updated: Jul 23, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 6, 2026

Data Sources Report a data error